Orbit Discovery

Orbit Discovery has developed a proprietary peptide synthesis and screening platform that can generate greater diversity than current methods.

Peptide drugs aim to combine the exquisite selectivity of antibodies while having the oral bioavailability of traditional small molecules. By screening large peptide libraries generated enzymatically using DNA primers encapsulated in microdroplets, Orbit performs early stage lead-discovery for pharmaceutical and biopharmaceutical drug development programs. The Company was spun out from the University of Oxford in January 2016 by Professors Graham Ogg and Terry Rabbitts of the Weatherall Institute of Molecular Medicine.

Visit website